G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 14.89 USD -3% Market Closed
Market Cap: 923.6m USD

GH Research PLC
PP&E Net

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

GH Research PLC
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
PP&E Net
$748k
CAGR 3-Years
96%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
PP&E Net
$1.1B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
PP&E Net
$250.1m
CAGR 3-Years
-5%
CAGR 5-Years
-1%
CAGR 10-Years
12%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
PP&E Net
$3m
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
5%
Cosmo Pharmaceuticals NV
SIX:COPN
PP&E Net
€29.1m
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
3%
Ovoca Bio PLC
LSE:OVB
PP&E Net
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GH Research PLC
Glance View

Market Cap
923.6m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
2.94 USD
Overvaluation 80%
Intrinsic Value
Price
G

See Also

What is GH Research PLC's PP&E Net?
PP&E Net
748k USD

Based on the financial report for Dec 31, 2024, GH Research PLC's PP&E Net amounts to 748k USD.

What is GH Research PLC's PP&E Net growth rate?
PP&E Net CAGR 3Y
96%

Over the last year, the PP&E Net growth was -30%. The average annual PP&E Net growth rates for GH Research PLC have been 96% over the past three years .

Back to Top